| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2002000617A3 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/30/2003 | WO2001091792A9 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | WO2001079286A3 Compositions and methods for the therapy and diagnosis of breast cancer |
| 01/30/2003 | WO2001025273A9 Compositions and methods for wt1 specific immunotherapy |
| 01/30/2003 | US20030023993 Nucleotide sequences coding polypeptide for use in the treatment of necrosis, septic shock and inflammation |
| 01/30/2003 | US20030023093 For use as antitumor agents |
| 01/30/2003 | US20030023088 To produce medicament for therapy and prophylaxis of cancer |
| 01/30/2003 | US20030023081 Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture |
| 01/30/2003 | US20030023079 For therapy of thrombosis in a mammal |
| 01/30/2003 | US20030023070 For diagnosis, prophylaxis and therapy; therapy of cancer |
| 01/30/2003 | US20030023061 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 01/30/2003 | US20030023050 Actinium-225 complexes and conjugates for targeted radiotherapy |
| 01/30/2003 | US20030023047 For prevention of influenza virus binding to cells, therapy of schizophrenia and diagnosing chronic viral disease associated with development of cancer |
| 01/30/2003 | US20030023038 For therapy of undesired cell proliferation; for stimulation and inhibition of lymphocytes |
| 01/30/2003 | US20030023034 p27 (Kip1) -FKBP-12 protein complexes |
| 01/30/2003 | US20030023033 Novel class II cytokine receptors and uses thereof |
| 01/30/2003 | US20030023031 Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| 01/30/2003 | US20030022918 (imidazoly-5-yl)methyl-2-quinolinone derivatives; antitumor agents |
| 01/30/2003 | US20030022909 Use of methylnaltrexone to treat immune suppression |
| 01/30/2003 | US20030022907 Anxiolytic agents and analgesics |
| 01/30/2003 | US20030022893 Hydroxamic and carboxylic acid derivatives |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022884 Heterocycle derivatives and drugs |
| 01/30/2003 | US20030022883 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 01/30/2003 | US20030022865 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 01/30/2003 | US20030022860 CD40 binding molecules and CTL peptides for treating tumors |
| 01/30/2003 | US20030022855 Melanoma differentiation associated gene-5 (mda-5) nucleic acids, proteins, and gene promoters for induction of apoptotic cell death |
| 01/30/2003 | US20030022853 Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 01/30/2003 | US20030022852 Biodegradable immunomodulatory formulations and methods for use thereof |
| 01/30/2003 | US20030022843 Toluene sulfonamide - containing anti- tumor composition and method of use thereof |
| 01/30/2003 | US20030022836 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 01/30/2003 | US20030022833 Inhibiting proliferation of a breast cancer cell which expresses a prolactin receptor, by exposing cell to a variant of human prolactin having a substitution of the glycine at position 129 |
| 01/30/2003 | US20030022822 Novel compounds |
| 01/30/2003 | US20030022821 A modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin seuquence |
| 01/30/2003 | US20030022819 Administering to an animal an angiogenic amount of a hedgehog polypeptide or agonist to promote angiogenesis |
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022338 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 01/30/2003 | US20030022312 Human hepatoma-derived growth factor-2 |
| 01/30/2003 | US20030022275 Human nk-3 related prostate specific gene-1 |
| 01/30/2003 | US20030022238 Methods of identifying agents which inhibit GPR-9-6 |
| 01/30/2003 | US20030022211 Nucleotide sequences coding polypeptide for use in diagnosis and prevention of psychological and nervous system disorders |
| 01/30/2003 | US20030022209 ADSLs as modifiers of the p53 pathway and methods of use |
| 01/30/2003 | US20030022183 Novel human G-protein coupled receptor, HGPRBMY7, expressed highly in spinal cord |
| 01/30/2003 | US20030022172 Polyamide nucleic acid derivatives and agents and processes for preparing them |
| 01/30/2003 | US20030022161 Diagnosing mammary gland cancer in humans; obtain ductal fluid sample, monitor marker gene product expression, amplified concentrations of marker products indicates cancer |
| 01/30/2003 | US20030022149 Enhanced production of safe plasma preparations |
| 01/30/2003 | US20030021854 Nanocrystal microbiocide metal |
| 01/30/2003 | US20030021838 Anticancer agents; vaccines; induction immunology response |
| 01/30/2003 | US20030021828 Method for treating and/or preventing retinal diseases with substained release corticosteroids |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021788 Novel human STRA6-like protein and nucleic acids encoding the same |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021786 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/30/2003 | US20030021785 Use of rank antagonists to treat cancer |
| 01/30/2003 | US20030021781 Administering antibodies |
| 01/30/2003 | US20030021779 Immunology response; monoclonal antibodies |
| 01/30/2003 | US20030021776 Regulation of angiogenesis with zinc finger proteins |
| 01/30/2003 | US20030021769 Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 01/30/2003 | US20030021768 Viral mutants that selectively replicate in targeted human cancer cells |
| 01/30/2003 | US20030021767 Recombinant p53 adenovirus methods and compositions |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | CA2454423A1 Method and reagents for identifying gene targets for treating breast cancer |
| 01/30/2003 | CA2454419A1 Invasion complex and methods of targeting |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2454345A1 Anti-tumor activity from reptile serum |
| 01/30/2003 | CA2454226A1 Improved heteropolymer complexes and methods for their use |
| 01/30/2003 | CA2454189A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 01/30/2003 | CA2454185A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | CA2453997A1 Porphyrin derivatives for photodynamic therapy |
| 01/30/2003 | CA2453993A1 Method and composition for treatment of cancer |
| 01/30/2003 | CA2453987A1 Dolastatin 10 derivatives |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453959A1 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres |
| 01/30/2003 | CA2453846A1 Substituted isoxazoles and the use thereof as antibiotics |
| 01/30/2003 | CA2453765A1 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | CA2453650A1 Substituted isoindoles and the use thereof |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453613A1 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453594A1 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| 01/30/2003 | CA2453342A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 01/30/2003 | CA2453296A1 Solvent-free anthracycline derivatives |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2453249A1 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/30/2003 | CA2453108A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452653A1 Silencing of gene expression by sirna |
| 01/30/2003 | CA2452541A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators |
| 01/30/2003 | CA2452518A1 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2451881A1 Novel bisphosphonate derivatives, their preparation methods and uses |
| 01/30/2003 | CA2450692A1 Tumor antigen |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/30/2003 | CA2418117A1 Antitumor agent |
| 01/30/2003 | CA2417955A1 Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them |